Literature DB >> 10614534

Molecular mechanisms of RET activation in human neoplasia.

M Santoro1, F Carlomagno, R M Melillo, M Billaud, G Vecchio, A Fusco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10614534     DOI： 10.1007/BF03343650

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  74 in total

1.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

Authors:  Y E Nikiforov; J M Rowland; K E Bove; H Monforte-Munoz; J A Fagin
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.

Authors:  R D Klein; D Sherman; W H Ho; D Stone; G L Bennett; B Moffat; R Vandlen; L Simmons; Q Gu; J A Hongo; B Devaux; K Poulsen; M Armanini; C Nozaki; N Asai; A Goddard; H Phillips; C E Henderson; M Takahashi; A Rosenthal
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

3.  Germline mutation of RET codon 883 in two cases of de novo MEN 2B.

Authors:  D P Smith; C Houghton; B A Ponder
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

4.  Radiation-induced thyroid cancer.

Authors:  E D Williams
Journal:  Histopathology       Date:  1993-10       Impact factor: 5.087

5.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

6.  Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5.

Authors:  S Klugbauer; E P Demidchik; E Lengfelder; H M Rabes
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

Review 7.  Genetic testing for cancer risk.

Authors:  B Ponder
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

8.  cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily.

Authors:  T Iwamoto; M Taniguchi; N Asai; K Ohkusu; I Nakashima; M Takahashi
Journal:  Oncogene       Date:  1993-04       Impact factor: 9.867

9.  High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident.

Authors:  S Klugbauer; E Lengfelder; E P Demidchik; H M Rabes
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

10.  Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.

Authors:  A Schuchardt; V D'Agati; L Larsson-Blomberg; F Costantini; V Pachnis
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962
View more
  7 in total

1.  RET proto-oncogene mutation in a mixed medullary-follicular thyroid carcinoma.

Authors:  F Orlandi; E Chiefari; P Caraci; A Mussa; I Gonzatto; P De Giuli; D Giuffrida; A Angeli; S Filetti
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

Review 2.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

Review 3.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

4.  ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Authors:  Claire Y Oh; Martin G Klatt; Christopher Bourne; Tao Dao; Megan M Dacek; Elliott J Brea; Sung Soo Mun; Aaron Y Chang; Tatyana Korontsvit; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2019-09-20       Impact factor: 11.151

5.  Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Authors:  Elisa Menicali; Sonia Moretti; Pasquale Voce; Serena Romagnoli; Nicola Avenia; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-22       Impact factor: 5.555

Review 6.  Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.

Authors:  Loredana Lorusso; Letizia Pieruzzi; Agnese Biagini; Elena Sabini; Laura Valerio; Carlotta Giani; Paolo Passannanti; Benedetta Pontillo-Contillo; Valentina Battaglia; Salvatore Mazzeo; Eleonora Molinaro; Rossella Elisei
Journal:  Onco Targets Ther       Date:  2016-10-20       Impact factor: 4.147

7.  Oncocytic Variant of Medullary Thyroid Carcinoma: A Rare Case of Sporadic Multifocal and Bilateral RET Wild-Type Neoplasm with Revision of the Literature.

Authors:  Gian Luca Rampioni Vinciguerra; Niccolò Noccioli; Claudia Cippitelli; Angelo Minucci; Ettore Capoluongo; Armando Bartolazzi
Journal:  Rare Tumors       Date:  2016-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.